NRX Pharmaceuticals (NRXP) Cash & Current Investments (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported Cash & Current Investments for 10 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 21.82% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 21.82% YoY), while the FY2025 annual figure was $7.8 million, up 440.33% from the prior year.
• Cash & Current Investments fell to $6.7 million in Q1 2026 per NRXP's latest filing, from $7.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $40.2 million in Q1 2022 and bottomed at $1.3 million in Q1 2024.
• Historically, Cash & Current Investments has averaged $10.8 million across 5 years, with a median of $7.2 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Current Investments plunged 92.01% — and 2025, when it surged 440.33%.
• NRX Pharmaceuticals' Cash & Current Investments stood at $20.1 million in 2022, then slumped by 77.09% to $4.6 million in 2023, then tumbled by 68.6% to $1.4 million in 2024, then soared by 440.33% to $7.8 million in 2025, then decreased by 14.07% to $6.7 million in 2026.
• Business Quant data shows NRXP's Cash & Current Investments at $6.7 million in Q1 2026, $7.8 million in Q4 2025, and $7.2 million in Q3 2025.